Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00642616 · ClinicalTrials.gov registry record · Phase 3
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3 study, sponsored by Mannkind Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 34
- Enrollment target
NCT00642616 is a Phase 3 study that was terminated before completion, run by Mannkind Corporation. The registered enrollment target is 34 participants.
The verdict
NCT00642616, a Phase 3 study, was terminated before completion, sponsored by Mannkind Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 34 participants
- Enrollment target
Study Summary
Examine the effects of TI in combination with an anti-diabetic regimen including inhaled insulin versus anti-diabetic treatment without inhaled insulin on lung function \& pulmonary safety
Interventions
- DRUG Usual Care
- DRUG Technosphere® Insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2009-03 |
| Est. Completion | 2014-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00642616
The ClinicalTrials.gov registry entry for NCT00642616 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Usual Care is the first listed.
NCT00642616 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00642616 about?
NCT00642616 is a clinical study titled "Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease". Examine the effects of TI in combination with an anti-diabetic regimen including inhaled insulin versus anti-diabetic treatment without inhaled insulin on lung function \& pulmonary safety
What is the current status of trial NCT00642616?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2009-03. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00642616?
The interventions under investigation include: Usual Care (DRUG), Technosphere® Insulin (DRUG).
Who is sponsoring clinical trial NCT00642616?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.